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WHAT THIS PAPER ADDS
 This research compared an endovascular aortic aneurysm repair (EVAR) follow-up protocol based on colour duplex ultrasound
(CDU) plus plain abdominal radiography (XR) and computed tomography (CT) angiography (CTA) on demand versus a CTA-based
protocol still considered the gold-standard technique of surveillance. Our study reports that CDU can be used in the follow-up of
patients after EVAR, as it is safe and picks up a similar rate of asymptomatic secondary interventions as a CTA-based surveillance
protocol. We do not advocate eliminating CTA completely from surveillance protocols, but would limit its use to circumstances in
which it can provide further details for problems ﬁrst detected by CDU examination. This approach could reduce costs, the risk of
contrast nephropathy and patients’ exposure to radiation. Thus, nearly 70% of CTAs have been eliminated from our surveillance
protocol.
In our opinion, surveillance should be simpliﬁed, adopting CDU as the main follow-up modality and only applying CTA as required
in certain circumstances.a r t i c l e i n f o
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Objectives: Literature reports that surveillance imaging followingendovascular aortic aneurysmrepair (EVAR)
gives rise to asymptomatic secondary interventions (SI) in 1.4e9% of cases. This retrospective study aimed to
evaluate whether the modality of surveillance imaging inﬂuences the detection rate of asymptomatic SI.
Materials and methods: Two EVAR surveillance protocols were compared at the same vascular centre.
Protocol I, performed from January 2003 to December 2006, consisted of colour duplex ultrasound scan
(CDU) plus CT angiography (CTA) 1 month after procedure and every 6 months thereafter. Protocol II,
performed from January 2007 to June 2010, consisted of CDU plus CTA 1 month after operation and CDU
plus plain abdominal ﬁlms (XR) every 6 months thereafter. In the second protocol, CTA was carried out
only during follow-up in speciﬁc conditions. The term ‘asymptomatic SI’ was used when the necessity for
SI was detected by imaging alone on an elective basis, prior to development of any symptoms.
Results: Enrolment included 376 and 341 consecutive patients with a mean follow-up of 1148 days (range
1e3204 days) and 942 days (range1e1512 days) in Protocols I and II, respectively (p < 0.001). Freedom
rates from aneurysmal rupture, freedom from SI and detection rate for asymptomatic SI at 3 years were
98.3% and 98.7% (p ¼ 0.456), 82% and 83.5%(p ¼ 0.876) and 8.8% (n ¼ 33/376) and 8.5%(n ¼ 25/341)
(p ¼ 0.49) in Protocols I and II, respectively. Estimated comparison of the costs, radiation exposure and
contrast used at 3 years in Protocol I versus Protocol II showed that Protocol II allowed for a three-, four-
and six fold reduction in overall costs, radiation exposure and contrast used, respectively (p < 0.0001).
Conclusions: The detection rate of asymptomatic SI following EVAR is not affected by the type of
surveillance imaging. A surveillance schedule based primarily on CDU and XR appears to be justiﬁed.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ciety for Vascular Surgery. PublisheLifelong follow-up is recommended for all patients following
endovascular aortic aneurysm repair (EVAR),the primary goal being
prevention of aneurysmal sac rupture. Various follow-upd by Elsevier Ltd. All rights reserved.
Table 1
Patient data. SD: standard deviation, CAD: coronary artery disease, CHF: congestive
heart failure, COPD: chronic obstructive pulmonary disease, renal insufﬁciency
serum creatinine > 1.5 mg/dl, ASA : American Society of Anesthesiology.
Protocol I (n ¼ 376) Protocol II (n ¼ 341) P value
Diameter (mm)
Mean (SD) 64 (6) 61 (8) <0.001
Range 50e99 50e112
Iliac aneurysm 86 (23%) 61 (18%) 0.119
Bilateral iliac aneurysm 41 (11%) 48 (14%) 0.241
Age
Mean (SD) 76.8 (8.7) 77.5 (7.0) 0.239
Range 67e90 66e92
Gender
Male/female 327/49 (87%/13%) 286/55 (84%/16%) 0.285
CAD 241 (64%) 208 (61%) 0.436
CHF 31 (8%) 31 (9%) 0.788
COPD 229 (61%) 201 (59%) 0.017
Renal insufﬁciency 169 (45%) 167 (49%) 0.315
Hypertension 278 (74%) 245 (72%) 0.586
Diabetes 124 (33%) 120 (35%) 0.586
Hypercholesterolemia 214 (57%) 203 (59%) 0.527
ASA
I e e
II 49 (13%) 41 (12%) 0.426
III 286 (76%) 252 (74%)
IV 41 (11%) 48 (14%)
Table 2
Type of stent graft implanted in the two protocols.
Stent graft Protocol I
N ¼ 376
Protocol II
N ¼ 341
p
Talent
Medtronic CardioVascular, Santa Rosa,
CA, USA
242 (64%) 144 (43%) <0.0001
Zenith
Cook Europe A/S, Bjaeverskov, Denmark 51 (13%) 16 (5%) <0.0001
Endurant
Medtronic CardioVascular,
Santa Rosa, CA, USA
e 168 (49%) e
Anaconda
Vascutek, Terumo, Inchinnan, Scotland, GB 17 (4%) 4 (1%) <0.05
Excluder
W.L. Gore & Associates, Flagstaff, AZ, USA 64 (19%) 9 (2%) <0.0001
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(XR), colour duplex ultrasonography (CDU), computed tomography
angiography (CTA), magnetic resonance imaging (MRI), contrast-
enhanced CDU and sac pressure measurement.13
The optimal protocol for imaging and timing EVAR follow-up is
debatable as well as the balance of advantages and disadvantages
for each modality. Follow-up includes measurement of aortic
aneurysm diameter, detection and classiﬁcation of endoleaks,
detection of morphologic details of the stent graft, graft occlusion,
graft infection and other minor details.13 A recent systematic
review reported that >90% of EVAR patients under follow-up do
not beneﬁt from surveillance since imaging alone initiates
asymptomatic secondary interventions (SI) ranging from 1.4% to
9%.4 The aim of this retrospective study was to evaluate whether
different modalities of surveillance imaging could inﬂuence the
detection rate of asymptomatic SI following EVAR. In particular, an
EVAR follow-up protocol based on CDU þ XR and CTA on demand
versus a CTA-based protocol, still considered the gold-standard
technique of surveillance, were compared.13 Other aims were to
evaluate the freedom from aneurysm rupture and SI, patients’
compliance to protocol, cost, radiation exposure and contrast
savings at 3 years. Three-year follow-up has been reported as
a good indicator for the efﬁciency of a surveillance regimen.5
Materials and Methods
Patient selection
Consecutive patients operated for asymptomatic AAA larger
than 5 cm were included in the study. All patients were treated
from January 2003 to June 2010 at a single University tertiary
referral centre. Patients were divided into two protocols. Patient
data are listed in Table 1. Anatomical suitability for EVAR included
proximal neck diameter <30 mm, angulation <75 and length
>12 mm. For distal implantation, at least one common iliac artery
with a distal diameter <24 mm was required. Patients with
signiﬁcant renal insufﬁciency (serum creatinine >2.5 mg/dl) but
not on dialysis, and those with a documented contrast allergy were
excluded from the study. The local Ethics Committee approved the
study and patients gave informed consent before the procedure.
Surgical procedure
All patients were treated in an operating theatre equipped with
a portable ﬂuoroscopy unit (GE-OEC 9800; GE Medical Systems,
Salt Lake City, UT, USA).
All stent grafts were aortobiiliac devices, but a variety of stent
grafts were used (Table 2). The stent grafts were routinely 10e15%
oversized. Bilateral femoral cut-down was performed in all
patients. Primary type I endoleaks were treated intra-operatively
with a giant Palmaz stent or proximal stent-graft extension.6
Follow-up protocols
The population was divided into two follow-up protocols.
Protocol I. From January 2003 to December 2006, all consecu-
tive EVAR patients were scheduled for a 1-month postoperative
follow-up consisting of CTA, CDU and clinical check-up. The same
examinations were performed every 6 months thereafter. The
change of surveillance regimen was dictated by the need to reduce
costs and provide a safer (reduced radiation exposure and contrast
agent use) less invasive follow-up for patients.
Protocol II. From January 2007 to June 2010, all consecutive
EVAR patients were scheduled for a 1-month postoperative follow-
up consisting of CTA, CDU, XR and clinical check-up. Thereafter,clinical check-up, CDU and XR were performed every 6 months. A
further CTA was performed when at least one of the following
elements were present: (a) aneurysmal sac growth>5mmwithin 6
monthsof follow-up, (b) onsetor persistenceof anykindof endoleak
and (c) suspected material fatigue/migration observed on XR.
CDU was performed by experienced vascular surgeons, using an
ATL HDI 5000 or IU 22 ultrasound system (Philips Medical Systems,
Bothell, WA, USA) with 2.5e5 MHz probes. After overnight fasting,
a sagittal or transverse scan of the supine patient was performed
using the probe. B-mode imaging was used initially to identify the
aorta, while the maximum diameter of the aneurysmal sac was
measured in the transverse plane. The patency of renal arteries was
conﬁrmed using spectral Doppler ultrasound. The aortawas scanned
from the proximal attachment site of the endograft to the distal
point. Using colour and spectral Doppler ultrasound, the stent was
assessed for perigraft ﬂow, graft stenosis, thrombosis, kinking and
endoleaks, according to the reporting standards for EVAR.7 Consis-
tent centring of the radiograph andprecise positioning of the patient
were carefully controlled and changes in correlations between
anatomical landmarks and stent-graft positionwere recordedduring
follow-up to detect structural failures or signiﬁcant graft migration.2
Table 3
Detection rate of ﬁndings in Protocol I from CTA as compared to CDU that lead to
asymptomatic SI.SI: Secondary intervention; CDU: colour duplex ultrasound; CTA
computed tomography angiography.
Indications for
asymptomatic SI
Total Detected
by CDU
n (%)
Detected
by CTA
n (%)
p Detected by
both modalities
Stent-graft limb kink 5 5 (100) 4 (80) 1 5 (100)
Type I endoleak 4 3 (75) 4 (100) 1 4 (100)
Type II endoleak 21 18 (86)a 16 (76)a 0.697 20 (95)a
Type III endoleak 2 2 (100) 2 (100) 1 2 (100)
Access site-related
problems
1 1 (100) 1 (100) 1 1 (100)
Sac expansion 27 26 (96) 27 (100) 1 27 (100)
Total 60 55 (92) 54 (90) 1 59 (98)
a Low ﬂow type II endoleak with sac expansion erroneously classiﬁed as endo-
tension by CTA and CDU. Angiography was required.
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(GEMedical Systems,Milwaukee,WI, USA)with a 3-mmacquisition
slice. A tri-phasic CT scan was performed on all patients at 30 days.
The30-daypostoperative CTscanﬁndingswere compared to the 30-
day CDU results and to the 30-day XR ﬁndings (Protocol II). The
ﬁndings of this ﬁrst postoperative CTA scan were considered the
baseline images for the entire follow-up. In Protocol I, the 6-month
CTAswerebiphasic, adding thedelayed phase only if required,while
in Protocol II CTA scan was tailored to the diagnostic queries that
arose following CDU. In the case of suspected structural problems,
material fatigue, type I or III endoleaks, a non-contrast and arterial
phases were performed. With suspected type II endoleak, arterial
and delayed phases were performed. In the enhanced CT, approxi-
mately 120 ml of Iodixanol 320 mg I ml1was used (Visipaque 
320mg Iml1, GEHealthcare, Buckinghamshire, UK). To avoid errors
caused by vessel tortuosity, the diameter measurements were
deﬁned as the smallest axis of the largest axial slice at CTA, XR and
CTA scans were analysed using an image-data post-processing
software program available at the imaging station (Advantage
Windows 3.1 or 4.1; Sun Microsystems, Mountain View, CA, USA).
Deﬁnitions and endpoints
The number of CTA, CDU and XR scans performed in both
protocols and the number of CTA scans deemed necessary in
Protocol II were assessed.
Primary technical success was assessed on an intention-to-treat
basis and deﬁned as successful implantation of a stent graft in the
absence of surgical conversion, mortality, type I or III endoleaks or
graft occlusion in the ﬁrst 24-h postoperative period. The clinical
endpoints were in accordance with the reporting standards for
EVAR7 and included 30-day mortality and late freedom from
abdominal aortic aneurysm (AAA)-related death.
Number/rate of asymptomatic and symptomatic SIs were noted.
The term ‘asymptomatic SI’ was used when the necessity for SI was
detected by imaging alone on an elective basis, prior to develop-
ment of any symptoms. The term ‘symptomatic SI’ was used when
the necessity for SI was driven by symptoms and triggered a diag-
nostic check-up. Indications for SI were noted. Complications
included any endoleaks, AAA expansion (deﬁned as increase >5
mm in postoperative diameter within 6 months of follow-up),
migration of the main graft (>1 cm at CT scan or XR), graft infec-
tion, graft thrombosis, conversion to open repair, postoperative
renal impairment (permanent elevation of serum creatinine >30%
over baseline and dialysis-free survival), bowel ischaemia and
myocardial infarction (deﬁned as elevation of either creatinine
kinase or CK-MB tomore than 2 times the upper limit of normal and
troponin T > 0.1 ng ml1, usually in the context of chest pain or
electrocardiogram changes).
Patients’ compliance to each study protocol was deﬁned as the
percentage of patients not lost to follow-up.
Cost, radiation exposure and contrast savings were estimated
for both protocols in a 3-year follow-up.
Study design
Data were collected prospectively in a computerised database.
All data were analysed retrospectively for the two groups on an
intention-to-treat basis.
Statistical analysis
Normal distribution and homogeneity of variance were
conﬁrmed by the KolmogoroveSmirnov and Levene’s tests,
respectively. Data are expressed as mean and standard deviation(SD) or as absolute frequency and percentage (%). The Chi-square or
Fisher’s exact test were used for all comparisons of proportions. The
continuous variables were compared using the Student’s t test.
Survival analysis was performed according to KaplaneMeier and
signiﬁcance was calculated with a log-rank test for pairwise
comparisons. A p value < 0.05 (two tailed) was considered statis-
tically signiﬁcant. All statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS) package, version
13.0 (SPSS Inc., Chicago, IL, USA).
Results
Consecutive patients enrolled during the study periodswere 376
in protocol I and 341 in protocol II. Mean follow-up was 1148 days
(range: 1e3204 days) and 942 days (range: 1e1512 days) in Protocol
I and II, respectively (p < 0.001). There were only two signiﬁcant
differences in the patients’ characteristics between the two proto-
cols: the distribution of chronic obstructive pulmonary disease (61%
in Protocol I vs. 59% in Protocol II; p¼ 0.017) and themean aneurysm
size, which was larger in Protocol I (p < 0.001). Balloon expandable
stents (Palmaz) and proximal extensions for intra-operative prox-
imal type I endoleak were used in nine and 12 patients and in 7 and
15 patients in Protocol I and II, respectively (p ¼ 0.45).
In Protocol I, the total number of CTAs was 3657 and CDUs 5478
while in Protocol II 489 and 3856 of these examinations were
performed, respectively. The number of XR performed in Protocol II
was 1094 while the number of CTAs deemed necessary was 148
(30%). Of these, 96 (65%) were due to aneurysmal sac growth
>5 mm within 6 months of follow-up, 44 (30%) to the onset or
persistence of any endoleak and eight (5%) to suspected material
fatigue/migration at XR. Moreover, CDU revealed 14 cases of kink/
stenos is that were further investigated by CTA.
In Protocol I, accuracy of CDU compared to CTA was 94.4%
(positive predictive value of 88.9% and negative predictive value of
95.3%). The detection rate of ﬁndings in Protocol I is shown in
Table 3. In Protocol II, positive CTA following abnormalities detec-
ted on CDU was present in 131/144 (91%). In particular, CTA did not
describe correctly six low-ﬂow type II endoleaks and ﬁve stenosis/
kinks at the level of the iliac limb due to the artifacts from calcium
and metal skeleton. In two cases even a not technically well-
performed CTA, with no late phase scan did not detect a type II
endoleak. When CTA was negative, CDU was considered the most
reliable modality of further follow-up. Angiographywas used as the
last diagnostic tool (only in one case, low-ﬂow type II endoleak).
Clinical outcomes are reported in Table 4. There were no statisti-
cally signiﬁcant differences between Protocol I and II in the rates of
primary technical success, 30-day mortality, late AAA-related
mortality or cardiac, renal or pulmonary complications. This
conﬁrms the safety of Protocol II versus Protocol I. In particular,
Table 4
Clinical outcomes. AAA: abdominal aortic aneurysm; SI: Secondary interventions.
Protocol I
(n ¼ 376)
Protocol II
(n ¼ 341)
p value
Primary technical success 367 (97.6%) 334 (97.9%) 0.956
30-day mortality 8 (2.1%) 6 (1.7%) 0.932
3-year freedom from
AAA-related mortality
94.9%
(19 deaths)
95.6%
(15 deaths)
0.814
3-year overall survival 83%
(64 deaths)
84%
(55 deaths)
0.764
Early proximal type I endoleak
(<30 days)
2 (0.5%) 1 (0.3%) 1.000
Late proximal type I endoleak
(>30 days)
4 (1.1%) 4 (1.2%) 1.000
Distal type I endoleak 1 (0.3%) 0 1.000
Type II endoleak 57 (15%) 45 (13.2%) 0.519
Type III endoleak 3 (0.8%) 3 (0.9%) 1.000
SIs 68 (18%) 56 (16.4%) 0.625
Sac expansion (>5 mm) 54 (14.4%) 43 (12.6%) 0.565
Migration (>1 cm) 2 (0.5%) 1 (0.3%) 1.000
Conversion to open repair 3 (0.8%) 1 (0.3%) 0.626
Aneurysm rupture 2 (0.5%) 1 (0.3%) 1.000
Renal impairment
Permanent
(>30% over baseline)
33 (8.7%) 29 (8.5%) 0.997
Need for dialysis 0 0 e
Myocardial infarction 16 (4.2%) 13 (3.8%) 0.912
Graft infection 0 0 e
Limb occlusion 10 (2.6%) 8 (2.3%) 0.977
Bowel ischaemia 2 (0.5%) 0 0.501
Table 6
A. Indications and timing for any secondary intervention (SI).Asymp: asymptomatic;
symp: Symptomatic; B. Causes for secondary intervention by the type of stent graft
used.T: Talent; Z: Zenith; EX: Excluder; A: Anaconda; E: Endurant.
A
Indications for SI Protocol I Protocol II p
Asymp/symp 33/35 25/31 0.802
Within 30 days after EVAR
Early SI 17 11 0.602
Asymp
2*/15 symp
Asymp
1*/10 symp
Access site-related problems 8 5 0.827
Bowel ischaemia 1 e 1.000
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and 98.7% (p ¼ 0.456) for Protocol II. Two ruptures occurred in
Protocol I and one in Protocol II. All ruptures occurred in patients
lost to follow-up who had a preoperative aneurysm larger than
7 cm and a nearly or late type Ia endoleak. The ruptures occurred at
44, 1067 and 508 days after EVAR. In one case, type I endoleak wasTable 5
KaplaneMeier plots of freedom from secondary interventions for protocol I and II.
SI : Secondary interventions.
1 year 2 years 3 years
Protocol I Patients at Risk 368.5 305 257
Events 46 12 7
Freedom from SI 88.5% 84% 82%
Protocol II Patients at Risk 338 277 184
Events 22 20 9
Freedom from SI 93% 87% 83.5%caused by proximal migration of the prosthesis due to the rupture
of the suprarenal stent. All ruptures were treated by emergency
conversion to open repair. A case of impending rupture due to
a massive type II endoleak was also treated by emergency conver-
sion to open repair (another case was treated endovascularly by coil
embolisation of the sac).
A total of 124 SIs were performed at 3 years (n ¼ 58; 8.1%
asymptomatic, n ¼ 66; 9.2% symptomatic). Three-year asymp-
tomatic SI rate was 8.8% (n ¼ 33/376) in Protocol I and 8.5%(n ¼ 25/
341) in Protocol II (p ¼ 0.49). Symptomatic SIs were relatively more
frequent within 30 days (n ¼ 25/28; 90%) while asymptomatic SIs
(n ¼ 55/96; 58%) were more likely to occur after 30 days.
SI-free survival rates at 3 years were 82% in Protocol I and 83.5%
in Protocol II (p¼0.876)(Table 5). Table 6A reports the indications
for SI in both protocols, divided into early (<30 days) and late (>30
days) and symptomatic or asymptomatic. Table 6B reports the type
of stent graft in which a different SI occurred. No statistically
signiﬁcant differences were found between the two protocols in the
detection rate of asymptomatic or symptomatic SI. Any comparisonStent-graft limb kink 1* 1* 1.000
Limb occlusion 3 2 1.000
Limb ischaemia 2 e 0.501
Type I endoleak 2 (1*) 1 1.000
Type III endoleak e 1 1.000
Blue toe syndrome 1 e 1.000
Renal infarct e 1 1.000
More than 30 days after EVAR
Late SI 51 45 0.621
Asymp
31*/20 symp
Asymp
24*/21 symp
Access site-related problems 5(1*) 4 1.000
Bowel ischaemia 1 e 1.000
Limb occlusion 2 4 0.408
Limb ischaemia 3 2 1.000
Stent-graft limb kink 5 (4*) 10 (6*) 0.050
Type I endoleak 5(3*) 4 (1*) 0.771
Type II endoleak 21* 17* 0.895
Impending rupture type II endoleak 1 1 1.000
Type III endoleak 3 (2*) 2 1.000
Rupture 2 1 1.000
Total 68 56
B
Cause for secondary intervention Protocol I Protocol II
Access site-related problems 14 (11T, 2Z, 1EX) 9 (5T, 3E, 1Z)
Bowel ischaemia 2 (1T, 1Z) e
Stent-graft limb kink 10 (7T, 2Z, 1EX) 17 (13T, 3E, 1Z)
Limb occlusion 5 (4T, 1Z) 6 (4T, 1Z, 1E)
Limb ischaemia 5 (3T, 1Z, 1EX) 2 (1T, 1E)
Type I endoleak 11 (9T, 1Z, 1 EX) 6 (3T, 3E)
Type II endoleak 21 (15T, 2Z, 1A, 3EX) 17 (7T, 1Z, 9E)
Impending rupture type II endoleak 1 (EX) 1 (T)
Type III endoleak 5 (3T, 1Z, 1EX) 3 (2T, 1E)
Rupture 2 (2T) 1 (T)
Blue toe syndrome 1 (Z) e
Renal infarct e 1 (E)
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not adequate to evaluate a statistical signiﬁcance. SIs were per-
formed mainly by endovascular means (63% of cases). We had
a signiﬁcant number of access problems in the 30-day follow-up
(symptomatic SIs). Some were related to bleeding at the level of
the groin but the most frequent were related to occlusive problems
(75%) due to dissection of very calciﬁed plaques at the level of the
external iliac artery or to the presence of a very diseased and
calciﬁed common femoral artery. The patients lost to follow-up
were 18 (4.8%, Protocol I) and ﬁve (1.5%, Protocol II) with a higher
level of patient compliance in Protocol II (p ¼ 0.018).
On 3-year analysis (p < 0.0001), Protocol I cost approximately
3000 euro while Protocol II about 1000 euro (when any CTA was
required). Each patient in Protocol I received an estimated dose of
151m Svwhile in Protocol II the estimated dosewas 35m Sv (when
any CTA was required). The quantity of contrast medium used was
one-sixth that used in Protocol II. Estimated comparison of Protocol
I versus Protocol II showed a threefold reduction of overall costs for
Protocol II (p < 0.0001).
Discussion
To our knowledge, this is the ﬁrst paper dealing with the
comparison of asymptomatic SI using two modalities of EVAR
surveillance. It reports similar ﬁndings using a protocol based
mainly on CDU plus XR and the other based on CTA.13 Regarding
the safety of the two protocols, there were no statistically signiﬁ-
cant differences in freedom from aneurysm rupture and SI rate. This
study highlights the fact that the majority of SIs are initiated by
symptoms rather than by a surveillance-imaging protocol, even
when carefully performed or when follow-up is based predomi-
nantly on CDU and XR. Speciﬁcally, 8.1% of patients beneﬁted from
surveillance imaging following EVAR. Literature reports that
imaging alone leads to a rate of asymptomatic SI ranging from 1.4%
to 9%.4,8e10 Therefore, the role of a CTA-based follow-up could be
questioned in favour of a less invasive protocol in many patients.9
The primary goal of EVAR follow-up is to prevent expansion of
the aneurysmal sac and rupture.13,8 Aneurysmal sac reduction
over time has been used as a surrogate marker for successful
exclusion, thrombosis of the aneurysmal sac and a decreased risk ofFigure 1. A proposed protocol of surveillance as currently performed in our center CDU:
abdominal radiography; SI: Secondary interventions.rupture.11 In fact, an increase of the sac after EVAR has been linked
to continued risk of rupture.2 A CDU-based surveillance programme
using increasing aneurysmal sac size as a trigger for SI showed no
negative effects on aneurysm-related survival.12 Some authors have
reported that diameter measurements of the residual sac, as well as
the detection of limb problems and endoleaks, could be evaluated
by CDU with a high level of accuracy.8,1316 By contrast, AbuR-
ahma17 reported that CDU could not diagnose type II endoleaks
with the same sensitivity as CTA, but afﬁrmed that any type II
endoleak that required SI would provoke an increase in the sac size,
which can be correctly diagnosed by CDU. Therefore, an SI could be
detected in time by CDU focussing on endoleaks or sac
enlargement.
Chaer et al.15 reported that CDU is safe as the sole long-term
post-EVAR surveillance method in patients with shrunk or stable
aneurysms, resulting in a 70% reduction of CTA scans. This ﬁnding is
similar to our CTA reduction rate in Protocol II (about 70%). CTA scan
in Protocol II was tailored to each patient to reduce unnecessary
invasive examinations. Our study does not advocate eliminating
CTA completely from surveillance protocols, but could limit its use
to circumstances that provide further details about problems ﬁrst
detected on CDU and XR examination.8,17 Alternative modalities of
surveillance have also been reported.2,4,18,19
In our study, a 3-year analysis of cost, radiation exposure and
contrast used allowed for a three to six fold reductionwith Protocol
II. Similarly, other studies reported a higher cost for CTA-based
EVAR surveillance regimen over a CDU-based protocol.16,20,21 The
cost of current (CTA-based) EVAR surveillance regimens is signiﬁ-
cant, accounting for 30e35% of the total costs of EVAR follow-up
over a 5-year period.20 CT imaging accounts for more than two-
thirds of the total costs of such surveillance protocols.21 EVAR
needs to demonstrate cost effectiveness and reducing surveillance
costs is certainly an essential step. According to Nordon et al.,4
surveillance is necessary and should be targeted to stent grafts
and patients at high risk for complications (large aneurysms, short
and/or angulated necks, early endoleaks and patients undergoing
adjunctive intra-operative procedures), thus suggesting that the
high costs of CTA-based surveillance may not be justiﬁed for all
patients.9,10 CDU can satisfy both the need to reduce costs and
patients’ demand for less invasive methods. Moreover, CDU hascolour duplex ultrasonography; CTA: Computed tomography angiography; XR: plain
E. Chisci et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 276e281 281zero potential morbidity22 and no risk of contrast nephropathy or
radiation exposure for patients.23,24
Symptomatic SI still occurs in daily practice and many are per-
formed within 30 days of stent-graft deployment. According to
various authors, incomplete immediate postoperative imaging
leads to many early SIs.4 Accurate intra-operative imaging, at least
two-view completion angiography4 or alternatively a Dyna-CT
scan,25 and a pre-discharge CDU can evaluate the completeness
of aneurysm exclusion and the absence of kinks, compression or
stenosis in a limb, allowing pre-emptive treatment thus reducing
the need for surveillance and SI.4,26
According to our ﬁndings, the current post-EVAR surveillance
regimen should be simpliﬁed, adopting CDU as the main follow-up
modality. Component separation and structural stability could be
effectivelyevaluatedonXR.2 CTA shouldonlybe appliedwhenadverse
events are suspected, remaining crucial, when SIs have to be planned.
The current EVAR follow-up protocol performed at our vascular
center is outlined in Fig. 1. The 30-day images can be considered as
the baseline value for surveillance and the key stage of the whole
protocol.
Limitations
The main limitations of this study were the retrospective nature
of the paper and the wide variety of endografts used as well as the
shift from the use of Talent to Endurant grafts in Protocol II. Patient
inclusion in Protocol I or II was not based on randomisation but on
the surveillance practice followed at our institution at the time. The
aneurysms in Protocol I were larger. Moreover, there was no
speciﬁc assessment of the categories at high risk for complications.
Lastly, CDU is an operator-dependent technique and some variables
depend on patients’ physical habits and the need for optimal
patient preparation. However, developing technologies and
extensive operator training have improved these limitations.2
Conclusions
Our study shows that detection rate of asymptomatic SI
following EVAR is not affected by the type of surveillance imaging.
The percentage of patients beneﬁting from surveillance was 8.1%,
while 9.2% were treated because of symptoms. The reduced inva-
siveness, cost, radiation exposure and contrast used of the
surveillance protocol based on CDU and XR appears to justify its use
in long-term EVAR follow-up, as also patients’ better compliance.
CTA is necessary in planning SI or in solving diagnostic problems
arising from a dubious CDU scan or XR.
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